Table 2.
Pharmacokinetic parameters of trans-resveratrol in rats after oral administration of raw trans-resveratrol or solid dispersions.
| Solid Dispersions (Trans-Resveratrol/Polymer Ratio) | AUC0→8h (ng·h/mL) | Cmax (ng/mL) | Tmax (h) | F (%) |
|---|---|---|---|---|
| Eudragit E/HCl (25/75) | 330.0 ± 41.8 a | 109.6 ± 22.4 a,b | 1.0 ± 0.3 | 22.6 |
| Eudragit E/HCl (10/90) | 583.9 ± 92.1 a,b,c | 204.4 ± 25.5 a,b,c | 0.8 ± 0.2 | 40.0 |
| HPMC (10/90) | 279.8 ± 40.7 a | 79.6 ± 11.2 a | 1.1 ± 0.4 | 19.2 |
| Raw trans-resveratrol | 138.9 ± 22.0 | 37.0 ± 7.7 | 1.2 ± 0.3 | 9.5 |
Note: a p < 0.05 vs. raw trans-resveratrol; b p < 0.05 vs. HPMC solid dispersion (10/90) c p < 0.05 vs. Eudragit E/HCl solid dispersion (25/75). Mean ± standard deviation (n = 5). AUC0→8 h, the area under the plasma concentration versus time curve; Cmax, the maximum plasma concentration of trans-resveratrol; Tmax, the time required to reach Cmax; F (%), the absolute oral bioavailability.